Incyte CEO Hervé Hoppenot took investors on a whirlwind tour of 18 events that could take place throughout 2025 during his recent presentation at the J.P. Morgan Healthcare Conference.

For the third year in a row, the hundreds of millions of dollars poured into commercials for AbbVie’s immunology blockbusters have earned the Big Pharma the top spot on the year’s list of the top TV drug ad spenders.

Fosun International’s proposed buyout of its partially owned subsidiary, Shanghai Henlius Biotech, has been quashed, with the necessary threshold of Henlius’ shareholders not voting in favor of the deal.

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year.

After revenue boomed for biopharma manufacturers during the COVID pandemic, sales have stagnated for several CDMO giants, but Korean powerhouse Samsung Biologics has somehow avoided the slide. The company has reported another robust increase in its top line, with a 23% sales boost, from 3.69 trillion Korean won in 2023 […]

Xeris Pharmaceuticals has teamed up with the American Diabetes Association to raise awareness of the importance of prescribing glucagon, positioning the partners to address a fundamental barrier to the use of products such as its Gvoke.